MENUNews Archive
Date: 03/03/2022
Researchers at the University of Michigan Rogel Cancer Center found that a cytokine, a category of protein that acts as messengers in the body, and a fatty acid can work together to trigger a type of cell death previously defined by studies with synthetic molecules.
Date: 03/03/2022
The surgeons at 21 melanoma referral centers collaborated to see whether these revelations had created changes in treatment plans for high-risk melanoma. It can often take significant time — as long as a decade — for providers to adopt or deescalate cancer treatments, even if the available evidence supports a shift in the landscape.
Date: 02/24/2022
A new phase II trial finds that PET scans obtained before and midway through treatment for p16-positive oropharynx cancer (OPC) can help determine whether a patient can receive a lower dose of radiation therapy in the second half of their treatment course without compromising cancer control.
Date: 02/16/2022
In 2005, Arul Chinnaiyan, M.D., Ph.D., and his lab found when a gene regulated by androgens called TMPRSS2 fuses with a transcription factor called ERG, it triggers the development of prostate cancer. This gene fusion was the first ever identified in solid tumors. In the nearly two decades since, the Chinnaiyan lab has refined its discovery, understanding how the hormone androgen regulates this gene fusion and developing a urine-based screening test to better detect prostate cancer.
Date: 02/13/2022
Arul M. Chinnaiyan, M.D., Ph.D., was awarded the 2022 Sjöberg Prize by the Royal Swedish Academy of Sciences, which also awards Nobel Prizes. Chinnaiyan is being honored for the discovery of recurrent gene fusions in prostate cancer, a groundbreaking finding initially published in 2005 that has led to a better understanding of how prostate cancer develops and improved methods to detect the disease.
Date: 02/10/2022
Evan Keller, D.V.M., Ph.D., associate director of shared resources at the Rogel Cancer Center, has been appointed to a new directorship in the University of Michigan’s Office of the Vice President for Research, according to Vice President for Research Rebecca Cunningham, M.D.
Date: 02/03/2022
A team of interdisciplinary researchers at the University of Michigan, backed by a $1 million W.M. Keck Foundation grant, has developed a high-risk, high-reward approach to understand how each cell in a population processes information and translates that to action driving cancer cell progression.
Date: 01/28/2022
Hyaluronic acid, or HA, is a known presence in pancreatic tumors, but a new study from researchers at Rogel Cancer Center shows that hyaluronic acid also acts as food to the cancer cells. These findings, recently published in eLife, provide insight into how pancreatic cancer cells grow and indicate new possibilities to treat them.
Date: 01/27/2022
The University of Michigan Rogel Cancer Center is home to seven members selected as 2021 fellows of the American Association for the Advancement of Science. These Rogel Cancer Center researchers are among 564 scientists, engineers and innovators spanning 24 scientific disciplines, recognized for their scientifically and socially distinguished achievements.
Date: 01/20/2022
The University of Michigan Health Rogel Cancer Center has named David C. Smith, M.D., chief medical officer and associate director for cancer clinical services, and Shruti Jolly, M.D., associate director for the Michigan Medicine statewide cancer network.